COL7A1 and recessive dystrophic epidermolysis bullosa: In multiple ex vivo studies, CRISPR/Cas9 has been harnessed to correct the COL7A1 mutation in induced pluripotent stem cells derived from patients with RDEB with subsequent transplantation onto mice of the skin equivalents grown from corrected keratinocytes [38,39,62,63,64].